of neuropathic pain, which was induced by L5 spinal nerve ligation (SNL). We observed that najanalgesin had antinociceptive effects on the central and peripheral system in a rat neuropathic pain model. [6] However, the effect of najanalgesin on the MAPK pathways after nerve injury remains unclear. In the present study, we investigated the effect of najanalgesin in rats using a neuropathic pain model, focusing on the MAPK family members' JNK, ERK, and p38 MAPK.
Methods

Drugs administration
The MAPK kinase (MEK) 1/2 inhibitor (PD98059; 0.1 μg/μl; EMD Biosciences, La Jolla, CA, USA), the p38 inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl) imidazole (SB203580; 0.5 μg/μl; Calbiochem, USA), and the JNK inhibitor anthrax [1,9-cd] pyrazol-6 (2H)-one (SP600125; 2.5 μg/μl; Calbiochem) were prepared in 50% dimethyl sulfoxide (DMSO). Both DMSO (50%) and normal saline were used as vehicle controls.
Rats were allowed to survive for up to 7 days after surgery. The doses used for intrathecal najanalgesin (40 ng/kg) were selected according to our pilot study. JNK, phosphor-JNK (Thr183/ Tyr185), phosphor-p38, phosphor-ERK, and phosphor-c-Jun antibodies were purchased from Cell Signaling Technology Inc., USA.
Animals
Male Sprague-Dawley rats (200-220 g) were purchased from the Laboratory Animal Center at Sun Yat-sen University. All procedures were conducted in accordance with the National Institutes of Health guidelines on animal care. The experimental design resulted in four groups of rats (n = 8 per group): (1) Control group of the sham-operated rats; (2) SNL group of rats with L5 spinal nerve ligation; (3) najanalgesin group of treatment injury rats with 40 ng/kg najanalgesin; (4) inhibitor group of treatment rats with PD98059 or SB203580 or SP600125. All rats were housed in separate cages with free access to food and water and maintained on a 12-h light/dark cycle. Efforts were made to minimize the number of animals used and their suffering.
Surgery
All experimental procedures were performed according to previously established methods. [6] A sterile polyethylene-10 catheter was inserted into the rat's lumbar subarachnoid space, and drugs were administered in a volume of 10 μl. The L5 spinal nerve was tightly ligated with silk suture. In sham-operated rats, the nerve was exposed without ligature. Special care was taken to prevent infection and minimize inflammation.
Behavioral testing
On each testing day, the rats were brought into the behavioral room at least 30 min prior to the test session. Mechanical sensitivity was assessed using the up-down method as previously described using a set of von Frey hairs (Ugo Basile, Italy). [6, 7] Western blotting Equal amounts of the samples were run on a 12% dodecyl sulfate-polyacrylamide gel and separated using SDS-PAGE. Antibodies against JNK (1:1000; Cell Signaling Technology), ERK (1:1000; Cell Signaling Technology), and p38 (1:1000; Cell Signaling Technology), as well as a monoclonal primary antibody against β-actin (mouse, 1:500; Boshide), were diluted in tris-buffered saline containing 0.1% Triton X-100 and 5% bovine serum albumin and used as primary antibodies. [8] 
Immunohistochemistry
Immunohistochemistry was performed on 25-μm free-floating L5 spinal cord sections as previously described. [7] Spinal cord sections were incubated overnight at 4°C with JNK primary antibody (1:1000) and subsequently incubated with a Cyc3-conjugated secondary antibody (1:6000, Boshide, China). To assess nonspecific staining, control sections were incubated in the absence of primary antibodies. The mean value of JNK-IR was obtained within the spinal dorsal horn laminae I-III from six randomly selected sections from each animal. [8] 
Statistical analysis
All data were expressed as the mean ± standard error (SE) of the mean. One-way analysis of variance (ANOVA) followed by Tukey's test was used for immunohistochemistry and western blotting data. A P < 0.05 was considered as statistically significant.
results
The rats subjected to the neuropathic pain model developed robust behavioral allodynia after SNL, which persisted for at least 2 weeks. Sham-operated rats showed no apparent response to mechanical stimuli at any of the investigated time points.
In the mechanical withdrawal threshold testing, groups of rats were injected intrathecally with saline, najanalgesin, or SP600125; the paw withdrawal threshold was measured for 24 h after injection. The injection of najanalgesin resulted in the significantly high threshold compared with saline treatment (P < 0.05) started 1 h and lasted past 24 h. SP600125 produced antinociceptive action than those observed with saline treatment at 1, 3, and 9 h after injection (P < 0.05), [ Figure 1 ]. Our study suggested that najanalgesin has a significant antinociceptive effect in a neuropathic pain model in rats. [6] To determine whether the inhibition of neuropathic pain by najanalgesin is regulated by the MAPK pathways, we examined the effect of najanalgesin on the phosphorylation levels of ERK, JNK, and p38 MAPK by Western blot analysis.
As shown in Figure 2 , p-p38 MAPK was consistently increased in the spinal dorsal cord of injured rats. However, there was no significant change after treatment with najanalgesin. When we investigated the possible role of ERK, we observed a significant increase in ERK phosphorylation levels after nerve injury. ERK activation was increased 10-fold in the SNL group compared with the control group. Interestingly, najanalgesin treatment had no effect on this increase in phosphorylated ERK (p-ERK) [ Figure 3 ].
Peripheral nerve injury significantly induced the activation of JNK without causing any significant changes in total JNK protein levels. JNK activation was increased by eight-fold in the SNL group compared with the sham group (P < 0.01). Interestingly, we observed a significant decrease in the phosphorylation of JNK at 3 and 9 h after treatment with 40 ng/kg najanalgesin [ Figure 4 ]. The phosphorylation of c-Jun followed a similar pattern to JNK after treatment with najanalgesin. The levels of phosphorylated c-Jun decreased progressively from 3 h to 9 h [ Figure 5 ]. Based on these results, we used three known pharmacological inhibitors of various MEKs to confirm the specificity of najanalgesin activity. We used inhibitors against ERK (PD98059), [9] p38 (SB203580), [10] and JNK (SP600125). [11] All of these inhibitors decreased the phosphorylation of p38 [ Figure 1 ], ERK [ Figure 2 ], and JNK [ Figure 3 ]. Western blotting revealed that rats subjected to nerve injury had increased levels of p-JNK, p38, and p-ERK. Treatment with najanalgesin inhibited the injury-induced increase in p-JNK, whereas p-ERK and p38 were unchanged. This result suggests that JNK may have a key role in the antinociceptive effect of najanalgesin on neuropathic pain.
The changes in JNK expression were confirmed by immunohistochemistry analysis. The robust increase of JNK expression in JNK-IR cells was observed in the superficial region (laminae I-III) of the dorsal horn. Low basal levels of constitutive JNK expression were observed in control group. However, intrathecal administration of najanalgesin effectively attenuated the increase in JNK expression. Consistent with the results obtained by western blot analysis, najanalgesin treatment of rats subjected to L5 SNL led to a decrease in ipsilateral JNK immunoreactivity at 3, 6, and 9 h compared with the control group [ Figure 6 ]. These findings suggest that the antinociceptive effect of najanalgesin inhibits JNK in a rat model of neuropathic pain.
dIscussIon
Increasing evidence has shown that MAPKs play important roles in the induction and maintenance of chronic pain. ERK, p38, and JNK represent three different signal transduction pathways that contribute to pain sensitization after tissue and nerve injury. [12] ERK, p38, and JNK are downstream of many kinases and are activated in primary sensory neurons, dorsal horn neurons, and spinal glial cells, and contribute to neuropathic pain via transcriptional, translational, and posttranslational regulation. [13] The inhibition of all three MAPK pathways has been shown to attenuate inflammatory and neuropathic pain in different animal models. [14] In the present study, we observed that peripheral nerve injury resulted in a marked increase in the activation of p38, ERK, and JNK (P < 0.01). The increased activation of both ERK and p38 MAPK was not attenuated by najanalgesin administration. However, the increase in JNK was attenuated with najanalgesin. The transcription c-Jun is the best-known substrate of JNK, and it is activated mainly through double phosphorylation by the JNK and also has a phosphorylation-independent function. [11] Our study showed that the levels of phosphorylated c-Jun were markedly increased in the SNL group and that this increase was prevented by najanalgesin treatment, which implies the involvement of JNK in the antinociceptive effect of najanalgesin. Consistent with these results, we also demonstrated by immunohistochemistry that the activation of JNK is involved in the antinociceptive effect of najanalgesin.
The MAPK pathways are complex and not yet fully understood, as different cell types respond to the same nerve injury by activating different signaling pathways. It has been suggested that the ERK pathway, which is primarily triggered in response to growth factors and mitogen stimulation, is involved in cellular proliferation and differentiation. [8] Specifically, ERK activation in spinal cord dorsal horn neurons occurs by nociceptive activity by regulating the activity of glutamate receptors and potassium channels, as well as inducing gene transcription. [15, 16] Based on our results, ERK may be not involved in the analgesic effect of najanalgesin treatment, suggesting that najanalgesin may act through another signaling pathway. p38 was shown to be rapidly and robustly activated in the superficial spinal dorsal horn after nerve injury and localized primarily to microglia. [17, 18] Peripheral nerve injury leads to the activation of both microglia and astrocytes in the spinal cord but with different time courses. [12] Microglia are involved in the early response to neuropathic pain, but the persistent expression of astrocyte markers correlates with the persistence of neuropathic pain symptoms. Activated glial cells release proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6, as well as other substances that enhance neuronal central sensitization and nerve injury-induced persistent pain. [19, 20] In this study, najanalgesin treatment was administered after the initial pain was inflicted and during the maintenance of the pain. Therefore, p38 may be not involved in antinociception of najanalgesin on the maintenance of neuropathic pain. Whether p38 would be involved in the antinociception with najanalgesin on the early response to neuropathic pain, we need to investigate it further.
The previous study showed that JNK is persistently activated in the spinal dorsal horn after nerve injury. [12] JNK has three isoforms: JNK1, JNK2, and JNK3. [21] JNK3 is primarily expressed in the brain and has different roles than JNK1 and JNK2. [22] However, JNK1 and JNK2 are heavily expressed in the spinal cord and are the predominant isoforms after nerve injury. [13] pJNK1/2 is persistently increased in astrocytes on 1, 3, 10, and 21 days in the spinal cord after partial sciatic nerve injury. [23] Additionally, c-Jun, the major transcription factor downstream of JNK, is also activated in the spinal cord after nerve injury. [11] The JNK/c-Jun pathway is activated in the spinal astrocytes, which is also critical for the maintenance of neuropathic pain. In this study, there were marked increases in the JNK and c-Jun levels after SNL, and both of these protein levels decreased after najanalgesin treatment. In addition, we have observed that astrocytes were involved in the antinociception of najanalgesin during the maintenance of pain in the previous study. [7] Therefore, the effect of najanalgesin may act through the JNK signaling pathway in the spinal cord on the maintenance of neuropathic pain.
CTX is the primary neurotoxic component of Crotalus durissus terrificus snake venom, which modulates inflammatory responses. This toxin inhibits cytokine release (e.g., IL-2, IL-4, and IL-10) in human serum albumin-immunized mice. [24] Our previous study showed that najanalgesin attenuated the activation of spinal astrocytes and reduced the release of proinflammatory cytokines (TNF-α, IL-1β) in the spinal cord. [7] Based on the results of our previous and current studies, najanalgesin produces an antinociceptive effect on the maintenance of neuropathic pain, by attenuating the activation of JNK, and reducing the release of proinflammatory cytokines. And then, we should investigate the mRNA of JNK and give JNK inhibitor to observe the expression of proinflammatory cytokines, in order to make the molecule mechanism of najanalgesin clear in the future.
The present study evaluates the intracellular signaling pathways implicated in the antinociceptive effect of najanalgesin, a toxin isolated from Naja naja atra. Najanalgesin inhibited JNK without affecting the activity of ERK and p38. This inhibition could be one of the mechanisms of najanalgesin that protects against peripheral nerve injury. The results suggest that the antinociceptive effect of najanalgesin is due to inhibition of JNK based on the neuropathic pain model. group (a, d, g ). Prominent astrocyte activation was observed in rats treated with intrathecal saline after spinal nerve ligation (b, e, h). These responses were markedly inhibited in rats treated with either intrathecal najanalgesin (c, f, i) or intrathecal SP600125 (j, k, l) for 3, 6, and 9 h. The c-Jun N-terminal kinase protein expression at all of the investigated time points was quantified and graphed. (a-i) ×200. The data are represented as the mean ± standard error of the mean. (n = 6). *P < 0.05 versus the control group; # P < 0.05 versus the spinal nerve ligation group. 
